BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 29741767)

  • 1. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
    Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
    Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
    Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
    Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnolol Enhances the Therapeutic Effects of TRAIL through DR5 Upregulation and Downregulation of c-FLIP and Mcl-1 Proteins in Cancer Cells.
    Woo SM; Min KJ; Kwon TK
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33050112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis.
    Siegmund D; Hadwiger P; Pfizenmaier K; Vornlocher HP; Wajant H
    Mol Med; 2002 Nov; 8(11):725-32. PubMed ID: 12520089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
    Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
    Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.
    Wang X; Chen W; Zeng W; Bai L; Tesfaigzi Y; Belinsky SA; Lin Y
    Mol Cancer Ther; 2008 May; 7(5):1156-63. PubMed ID: 18483303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
    Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
    Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
    Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
    J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2.
    Martín-Pérez R; Niwa M; López-Rivas A
    Apoptosis; 2012 Apr; 17(4):349-63. PubMed ID: 22072062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.
    Nathwani SM; Greene LM; Butini S; Campiani G; Williams DC; Samali A; Szegezdi E; Zisterer DM
    Int J Oncol; 2016 Jul; 49(1):74-88. PubMed ID: 27176505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
    Bellail AC; Tse MC; Song JH; Phuphanich S; Olson JJ; Sun SY; Hao C
    J Cell Mol Med; 2010 Jun; 14(6A):1303-17. PubMed ID: 19432816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression.
    Kelly MM; Hoel BD; Voelkel-Johnson C
    Cancer Biol Ther; 2002; 1(5):520-7. PubMed ID: 12496481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
    Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
    Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.